BriaCell Therapeutics Corp. Warrant (BCTXZ)
BriaCell Therapeutics Corp. Warrant operates in the Biotechnology industry of the Healthcare sector, headquartered in West Vancouver, BC, CA. The stock last traded at $0.10, up 0.10% on the session, giving a market capitalisation of $188,374. On trailing twelve-month figures it carries a trailing P/E of -0.28, a net margin of 0.0%. Its beta of 1.54 implies it has historically moved more than the broad market.
BriaCell Therapeutics Corp., a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, a personalized, ready-to-use immunotherapy intended for advanced breast cancer, and BriaDx, a diagnostic tool for determining patient HLA types. BriaCell maintains a non-exclusive clinical trial collaboration with Incyte Corporation to explore the effects of combining various novel clinical candidates. Furthermore, a cooperative research and development agreement with the National Cancer Institute supports preclinical efforts to advance and test Bria-OTS cellular immunotherapy as a cancer therapy.
BriaCell Therapeutics Corp. Warrant is most often compared with the following Healthcare names: